Frova is a drug owned by Endo Operations Ltd. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 07, 2015. Details of Frova's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5464864 | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(9 years ago) |
Expired
|
| US5827871 | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(9 years ago) |
Expired
|
| US5637611 | Medicaments |
Jun, 2014
(10 years ago) |
Expired
|
| US5616603 | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(10 years ago) |
Expired
|
| US5962501 | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Frova is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Frova's family patents as well as insights into ongoing legal events on those patents.
Frova's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Frova's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 07, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Frova Generic API suppliers:
Frovatriptan Succinate is the generic name for the brand Frova. 4 different companies have already filed for the generic of Frova, with Amneal Pharms Co having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Frova's generic
How can I launch a generic of Frova before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Frova's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Frova's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Frova -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2.5 mg | 09 Mar, 2011 | 1 | 08 Jul, 2014 | 07 Nov, 2015 | Eligible |
Alternative Brands for Frova
Frova which is used for the acute treatment of migraine attacks in adults., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Frova
Frova is a drug owned by Endo Operations Ltd. It is used for the acute treatment of migraine attacks in adults. Frova uses Frovatriptan Succinate as an active ingredient. Frova was launched by Endo Operations in 2001.
Approval Date:
Frova was approved by FDA for market use on 08 November, 2001.
Active Ingredient:
Frova uses Frovatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Frovatriptan Succinate ingredient
Treatment:
Frova is used for the acute treatment of migraine attacks in adults.
Dosage:
Frova is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2.5MG BASE | TABLET | Prescription | ORAL |